MedAware is proud to partner with Ballad Health, to leverage artificial intelligence (AI) to improve patient safety by identifying potential medication-related errors and improving operational efficiency within the pharmacy. Click here to read more.
Founders and Board Members
Chief Executive Officer
David Franklin joined MedAware as CEO to accelerate the company’s growth and to scale the company as it more aggressively enters the US market. He brings with him decades of entrepreneurial experience building and scaling health tech companies. He found his passion for early-stage growth companies as co-founder and COO of Connance, a healthcare predictive analytics company acquired by Waystar. Franklin also drove commercial success, enterprise profitability and business transformation in prior executive roles at Waystar, Finvi and Atlas Health. He splits his time in the US between Boston and La Jolla.
Gidi Stein, MD, PhD
Co-Founder and Chief Scientific Officer
Gidi is a practicing physician, researcher and serial entrepreneur. Early in his career, Gidi served as CTO and Chief Architect of several algorithm-rich startup companies in Israel. In 2002, Gidi graduated from Tel Aviv University Medical School and later specialized in internal medicine, treating patients and teaching students and residents in one of Israel’s largest hospitals. Gidi received a PhD in Computational Biology from Tel Aviv University, harnessing mathematical and biological models to help fight breast cancer. In 2012 Gidi co-founded MedAware, utilizing machine learning algorithms to eliminate medication-related risks and promote patient safety.
Laly leads business development and strategic relationships for OurCrowd and its portfolio companies. Before joining OurCrowd, Laly held senior positions in business development and strategy across multiple industries in private and public companies. She also experienced the rollercoaster of being the CEO of a startup making eco-friendly cardboard products. Laly began her career as a lawyer and enjoyed six years in the upper west side of New York working at a leading firm on mergers & acquisitions and securities offerings. Laly served as a non-commissioned Education Officer in the IDF Officers School. She holds both a law degree (1997) and a Philosophy degree (1997, magna cum laudae) from Tel-Aviv University and an MBA from the Nash Honors Program at Baruch College (2000). Laly is a long distance runner and enjoys hiking with her family.
Tuvik Beker, PhD
Co-Founder and Executive Chairman of the Board
Tuvik has 15+ years of experience in the IT industry. He has served in roles of VP, chairman, and CEO and as an independent algorithmic consultant to organizations ranging from VC-backed startups to market-leading corporations. Tuvik brings to MedAware a unique combination of rich entrepreneurial experience, academic expertise in artificial intelligence, and hands-on experience in algorithmic development.
Prof. Eytan Ruppin, MD, PhD
Eytan is a Professor of Computer Science and Medicine and a member of the Center for Bioinformatics and Computational Biology at the University of Maryland. His lab is an international leader in human metabolic modeling and he is an established authority in the areas of biomedical modeling and machine learning. He is a member of the editorial board of Artificial Intelligence in Medicine (AIM) and other journals on the interface of Computers and Medicine. Eytan has over 180 publications in leading scientific journals.
Allen is the co-founder and managing partner of Qure Ventures, Israel’s first exclusively focused digital health venture capital fund. A successful healthcare entrepreneur and corporate executive, Allen previously was a co-founder of Humedica, a transformative digital health company which was sold in 2013 to UnitedHealth (the largest U.S. health insurer). Following the acquisition, Allen served as the Chief Commercial Officer of Optum Analytics (a division in Optum, UnitedHealth Group’s health services company). With 25+ years of health care experience, Allen also was a director at leading healthcare investment bank, Leerink Swann (SVB Leerink), and held management positions at Biogen. He began his career reporting on FDA and policy issues for The Pink Sheet, and received his BA from Brandeis University.
Mr. Renzong Wang
Mr. Renzong Wang is the Chairman of Hubei Forbon Technology Co., Ltd., the Executive Director and General Manager of Wuhan Novec Bio-Materials Co., Ltd., the Representative of the Fourth People’s Congress of Xiaogan City, the Standing Committee Member of Seventh People’s Congress of Yingcheng City, the Executive Member of Science and Technology Association of Yingcheng City and the President of the Fine Chemicals Association of Yingcheng City. Previously, Mr. Wang served as the Head of Research and Development in Zhongshan Wynn Daily Chemical Co., Ltd., the General Manager in Zhongshan Green Wind Chemical Products Co., Ltd., the Deputy General Manager, General Manager, and the Executive Director of Yingcheng City Fubon Technology Co., Ltd from November 1995 to January 2007.
Yoav is a private investor in technology and private equity ventures, with experience in both public and private sectors in various international markets.
Yuri is the Senior Director of Becton Dickinson’s Global Ambulatory Infusion business. In this role, he directs a globally dispersed and cross-functional team of almost 300 associates that continues to grow at a double-digit rate annually. Yuri has more than 15 years of cumulative experience in various business development and strategy roles in the Medical Device and IT industries. Yuri received his MBA from the University of Michigan and a BS degree in Medical Sciences from the Hebrew University of Jerusalem.